Brief: Allergy Therapeutics Screening For Grass MATA MPL to Complete By Early Q1 2026
30/10/2025 07:21
Oct 30 (Reuters) - Allergy Therapeutics PLC AGY.L: ALLERGY THERAPEUTICS - G308 PHASE III YEAR 2 PATIENT SCREENING STARTS ALLERGY THERAPEUTICS PLC - SCREENING FOR GRASS MATA MPL TO COMPLETE BY EARLY Q1 2026 ALLERGY THERAPEUTICS PLC - SHORT-TERM SAFETY DATA EXPECTED IN Q4 2025 Source text: ID:nRSd4066Fa Further company coverage: AGY.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allergy Therapeutics
See all newsBrief: Allergy Therapeutics Expects FY 2026 Revenue Of £59.90 Million, Up 9% Reported
UK's Allergy Therapeutics FY revenue beats on Grassmuno launch
Allergy Therapeutics - Trading update for the year ended 30 June 2026
Brief: Allergy Therapeutics Appoints Helge Weiner-Trapness As Executive Chairman
Allergy Therapeutics - Appointment of Executive Chairman